Results 61 to 70 of about 112,082 (305)

Effect of amaranth proteins on the RAS system: In vitro, in vivo and ex vivo assays [PDF]

, 2020
The aim of this work was to analyse the hypotensive effect of amaranthprotein/peptides on spontaneously hypertensive rats (SHR). The mechanism of action of these peptides was studied in vivo and ex vivo.
Aphalo, Paula, Añon, Maria Cristina, Quiroga, Alejandra Viviana, Rinaldi, Gustavo Juan, Suárez, Santiago   +4 more
core   +2 more sources

Sex as a biological variable in nonclinical studies: Bridging scientific rigor, animal welfare, and regulatory expectations

Animal Models and Experimental Medicine, EarlyView.
Sex as a biological variable (SABV) is a critical determinant of pharmacokinetics, pharmacodynamics, and toxicity in nonclinical studies. This review highlights how inappropriate neglect of sex differences compromises animal welfare, scientific reproducibility, and regulatory compliance.
Kenta Onuma, Masaki Watanabe, Nobuya Sasaki   +2 more
wiley   +1 more source

Late Deprescribing of Angiotensin-Converting-Enzyme Inhibitors and Renin-Angiotensin Blockers in Patients with Advanced Cancer Receiving Palliative Care

Palliative Medicine Reports
Background: Treatment with antihypertensives in patients with advanced cancer is often continued until very late in the disease trajectory, despite a considerable risk of hypotension.
Linda Björkhem-Bergman, Christel Hedman, Máté Szilcz, Gabriella Frisk   +3 more
doaj   +1 more source

Assessment and Management of Hypertension among Patients on Peritoneal Dialysis [PDF]

, 2019
Approximately 7%-10% of patients with ESKD worldwide undergo peritoneal dialysis (PD) as kidney replacement therapy. The continuous nature of this dialytic modality and the absence of acute shifts in pressure and volume parameters is an important ...
Agarwal, Rajiv, Georgianos, Panagiotis I., Liakopoulos, Vassilios, Vaios, Vasilios   +3 more
core   +1 more source

Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Evaluate performance of the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator in rheumatoid arthritis (RA). Methods Patients with RA were matched up to 10 controls on age, sex, and enrollment year using National Veterans Health Administration, Medicare, and National Death Index data (2006–2020).
Tate M. Johnson, Halie Frideres, Punyasha Roul, Joshua F. Baker, Brian C. Sauer, Grant W. Cannon, Isaac D. Smith, Gary A. Kunkel, Beth I. Wallace, Thomas R. Porter, Kaveh R. Bookani, Amarnath R. Annapureddy, Ted R. Mikuls, Bryant R. England   +13 more
wiley   +1 more source

Drug-induced gingival enlargement: Series of cases

Universidad y Salud, 2018
Introduction: Gingival enlargement (GA) is a benign condition of the oral cavity that is characterized by the excessive growth of the gingiva in mass and volume.
Isabella Manzur-Villalobos, Ivan Alejandro Díaz-Rengifo, Daniella Manzur-Villalobos, Antonio José Díaz-Caballero   +3 more
doaj   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

PROBLEMS IN PHARMACOTHERAPY OF RESISTANT ARTERIAL HYPERTENSION

Российский кардиологический журнал, 2013
The paper focuses on the problems in the treatment of patients with resistant arterial hypertension. The relevant recommendations from the European guidelines are presented.
N. V. Teplova, E. O. Taratukhin
doaj   +1 more source

Is it time to reappraise blood pressure thresholds and targets? Statement from the international society of hypertension - a global perspective [PDF]

, 2016
No abstract ...
Burrell, Louise M., Horiuchi, Masatsugu, Poulter, Neil R., Prabhakaran, Dorairaj, Ramirez, Agustin J., Schiffrin, Ernesto L., Schutte, Alta E., Touyz, Rhian, Wang, Ji-Guang, Weber, Michael A.   +9 more
core   +2 more sources

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source